Rheumatoid Arthritis Therapeutics Market Size, Share and Industry Analysis By Product Type (Biologics, Non-Biologics), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Rheumatoid Arthritis Therapeutics Market with respect to COVID-19 Business Impact.
Inquire before buying

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders.50-70% of patients with RA are unable to achieve sustained clinical remission despite the availability of several treatments including disease-modifying anti-rheumatic drugs (DMARDS) like methotrexate, interleukin-6 (IL-6) blockers, and tumor necrosis factor (TNF) inhibitors. New therapeutic developments target other inflammatory pathways implicated in RA including the Janus kinase (JAK) signaling pathway as seen with filgotinib.

This report focuses on the Rheumatoid Arthritis Therapeutics market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Rheumatoid Arthritis Therapeutics market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Rheumatoid Arthritis Therapeutics Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Rheumatoid Arthritis Therapeutics Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Rheumatoid Arthritis Therapeutics Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

 	
Pfizer Inc.
 	
Amgen Inc.
 	
Johnson & Johnson Services, Inc.
 	
CELGENE CORPORATION
 	
Bristol-Myers Squibb Company
 	
Hoffmann-La Roche Ltd
 	
UCB S.A.
 	
Eli Lilly and Company
 	
Gilead Sciences, Inc.
 	
Other players

Report Coverage

The increasing prevalence and rising awareness about breathing disorders have resulted in demand for rheumatoid arthritis therapeutics. Additional factors expected to contribute to the growth of the market include the favorable reimbursement policies for expensive drugs in the U.S., the increasing geriatric population in developed and developing countries, and increased diagnostic capabilities in developing countries. The introduction of new products in the market, along with an increasing number of patients undergoing rheumatoid arthritis treatment globally is projected to further augment the demand for rheumatoid arthritis therapeutics during the forecast period.

The report provides qualitative and quantitative insights on the rheumatoid arthritis therapeutics industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market segments include product type, distribution channel, and geography. On the basis of product type, the market for rheumatoid arthritis therapeutics can be segmented into biologics and non-biologics.

Non-biologics can further be sub-segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drug (SDMARDs), and others. On the basis of distribution channels, the global rheumatoid arthritis therapeutics market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.

Along with this, the report analysis includes market dynamics and competitive landscape. The report also offers key insights related to pipeline analysis, the regulatory scenario for key countries, pricing analysis, key industry developments, incidence & prevalence of rheumatoid arthritis, snapshot on the novel & upcoming therapies, and an overview of treatment plans for rheumatoid arthritis.

SEGMENTATION

By Product Type

 	
Biologics
 	
Non-Biologics
 	
Non-Steroidal Anti-Inflammataory Drugs (NSAIDs)
 	
Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
 	
Others

By Distribution Channels

 	
Hospital Pharmacy
 	
Retail Pharmacy
 	
Online Pharmacy

By Geography

 	
North America (USA and Canada)
 	
Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
 	
Asia Pacific (China, India, Japan, Australia, Southeast Asia, and Rest of Asia Pacific)
 	
Latin America (Brazil, Mexico, and Rest of Latin America)
 	
Middle East & Africa (GCC Countries, South Africa, Rest of Middle East & Africa)

Key Industry Developments

In October 2020, Gilead Sciences Ireland UC received marketing authorisation valid throughout the European Union for Jyseleca(Filgotinib) which is a medicine for treating adults with moderate to severe rheumatoid arthritis, a disease in which the immune system (the body’s natural defences) attacks healthy tissue to cause inflammation and pain in joints. Jyseleca is used alone or with another medicine, methotrexate, after treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs) has not worked well enough or causes unacceptable side effects. DMARDs are medicines, such as methotrexate, that slow down worsening of the disease.

Jyseleca contains the active substance filgotinib. The newly approved filgotinib is a highly selective JAK1 inhibitor, JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy. Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.

In April 2017, Unichem Laboratories received approval from the US FDA for Piroxicam Capsules for the treatment of osteoarthritis and rheumatoid arthritis.

A targeted methotrexate prodrug to mitigate the toxicity in the treatment of patients with rheumatoid arthritis is being developed by a Danish start-up company ROS Therapeutics